SK4694A3 - 9h-imidazo (1,2,-a) benzimidazole-3-acetamide derivatives method of their preparation and pharmaceutical compounds containing these derivatives - Google Patents
9h-imidazo (1,2,-a) benzimidazole-3-acetamide derivatives method of their preparation and pharmaceutical compounds containing these derivatives Download PDFInfo
- Publication number
- SK4694A3 SK4694A3 SK46-94A SK4694A SK4694A3 SK 4694 A3 SK4694 A3 SK 4694A3 SK 4694 A SK4694 A SK 4694A SK 4694 A3 SK4694 A3 SK 4694A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- imidazo
- formula
- solvent
- water
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 title claims description 3
- JGUIKGIYNJGAGH-UHFFFAOYSA-N 2-(benzimidazol-1-yl)acetamide Chemical class C1=CC=C2N(CC(=O)N)C=NC2=C1 JGUIKGIYNJGAGH-UHFFFAOYSA-N 0.000 title description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 61
- -1 alcoxy Chemical group 0.000 claims abstract description 41
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000004429 atom Chemical group 0.000 claims abstract description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 63
- 239000002904 solvent Substances 0.000 claims description 53
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 239000012442 inert solvent Substances 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 239000003586 protic polar solvent Substances 0.000 claims description 10
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- IXPZYJRRDFZWHJ-UHFFFAOYSA-N 4h-imidazo[1,2-a]benzimidazole Chemical class C1=CC=C2N3C=CN=C3NC2=C1 IXPZYJRRDFZWHJ-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000000460 chlorine Chemical group 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000011737 fluorine Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- FAZSQMPWHSZJEZ-UHFFFAOYSA-N OCS(=O)CO.[Na] Chemical compound OCS(=O)CO.[Na] FAZSQMPWHSZJEZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 2
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical class NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000000949 anxiolytic effect Effects 0.000 abstract description 4
- 230000000147 hypnotic effect Effects 0.000 abstract description 4
- 208000019901 Anxiety disease Diseases 0.000 abstract description 3
- 230000001773 anti-convulsant effect Effects 0.000 abstract description 3
- 230000036506 anxiety Effects 0.000 abstract description 3
- 239000002249 anxiolytic agent Substances 0.000 abstract description 3
- 206010002091 Anaesthesia Diseases 0.000 abstract description 2
- 208000008238 Muscle Spasticity Diseases 0.000 abstract description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract description 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract description 2
- 230000037005 anaesthesia Effects 0.000 abstract description 2
- 229940035676 analgesics Drugs 0.000 abstract description 2
- 239000000730 antalgic agent Substances 0.000 abstract description 2
- 208000010877 cognitive disease Diseases 0.000 abstract description 2
- 206010015037 epilepsy Diseases 0.000 abstract description 2
- 229960005015 local anesthetics Drugs 0.000 abstract description 2
- 239000003158 myorelaxant agent Substances 0.000 abstract description 2
- 238000009101 premedication Methods 0.000 abstract description 2
- 208000019116 sleep disease Diseases 0.000 abstract description 2
- 208000018198 spasticity Diseases 0.000 abstract description 2
- 230000007428 synaptic transmission, GABAergic Effects 0.000 abstract description 2
- 229940124326 anaesthetic agent Drugs 0.000 abstract 2
- 230000003444 anaesthetic effect Effects 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 238000001949 anaesthesia Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004118 muscle contraction Effects 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 82
- 239000000203 mixture Substances 0.000 description 72
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 44
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 36
- 238000001914 filtration Methods 0.000 description 35
- 239000000047 product Substances 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000002844 melting Methods 0.000 description 28
- 230000008018 melting Effects 0.000 description 28
- 239000007787 solid Substances 0.000 description 27
- 239000000725 suspension Substances 0.000 description 22
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 239000002198 insoluble material Substances 0.000 description 9
- 239000001632 sodium acetate Substances 0.000 description 9
- 235000017281 sodium acetate Nutrition 0.000 description 9
- ZFCXPRXCTKPYEO-UHFFFAOYSA-N 2,2-diethoxy-n,n-dimethylacetamide Chemical compound CCOC(OCC)C(=O)N(C)C ZFCXPRXCTKPYEO-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000012265 solid product Substances 0.000 description 6
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- YDCIPRUDAYHVLT-UHFFFAOYSA-N 2-(7-chloro-4-methyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)acetic acid Chemical compound N1=C2N(C)C3=CC=C(Cl)C=C3N2C(CC(O)=O)=C1C1=CC=CC=C1 YDCIPRUDAYHVLT-UHFFFAOYSA-N 0.000 description 3
- LOYLEFYQOSIFBB-UHFFFAOYSA-N 2-phenyl-3h-imidazo[1,2-a]benzimidazole Chemical compound N1C2=NC3=CC=CC=C3N2C=C1C1=CC=CC=C1 LOYLEFYQOSIFBB-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- AFHSZBKDUTWXDX-UHFFFAOYSA-N 2-(benzimidazol-1-yl)acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=NC2=C1 AFHSZBKDUTWXDX-UHFFFAOYSA-N 0.000 description 2
- YCCYMDQQDBHRAU-UHFFFAOYSA-N 2-[4-ethyl-2-(4-methylphenyl)imidazo[1,2-a]benzimidazol-1-yl]acetamide Chemical compound N1=C2N(CC)C3=CC=CC=C3N2C(CC(N)=O)=C1C1=CC=C(C)C=C1 YCCYMDQQDBHRAU-UHFFFAOYSA-N 0.000 description 2
- SLGZKQAPZYSXRF-UHFFFAOYSA-N 2-[4-ethyl-2-(4-methylphenyl)imidazo[1,2-a]benzimidazol-1-yl]acetic acid Chemical compound N1=C2N(CC)C3=CC=CC=C3N2C(CC(O)=O)=C1C1=CC=C(C)C=C1 SLGZKQAPZYSXRF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- RPTBXHOSUIJJEO-UHFFFAOYSA-N n-methyl-2-[4-methyl-2-(4-methylphenyl)imidazo[1,2-a]benzimidazol-1-yl]acetamide Chemical compound N1=C2N(C)C3=CC=CC=C3N2C(CC(=O)NC)=C1C1=CC=C(C)C=C1 RPTBXHOSUIJJEO-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- BGYPHYAFWDUNDD-UHFFFAOYSA-N 1h-benzimidazole;sodium Chemical compound [Na].C1=CC=C2NC=NC2=C1 BGYPHYAFWDUNDD-UHFFFAOYSA-N 0.000 description 1
- WFVKIANRKSZMGB-UHFFFAOYSA-M 2,2-diethoxyacetate Chemical compound CCOC(C([O-])=O)OCC WFVKIANRKSZMGB-UHFFFAOYSA-M 0.000 description 1
- NGQQUXXTDZADNX-UHFFFAOYSA-N 2,3,4,5-tetrachlorofuran Chemical compound ClC=1OC(Cl)=C(Cl)C=1Cl NGQQUXXTDZADNX-UHFFFAOYSA-N 0.000 description 1
- FQPPPGUWQQJEOH-UHFFFAOYSA-N 2-(4,7-dimethyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)-2-hydroxy-n,n-dimethylacetamide Chemical compound N1=C2N(C)C3=CC=C(C)C=C3N2C(C(O)C(=O)N(C)C)=C1C1=CC=CC=C1 FQPPPGUWQQJEOH-UHFFFAOYSA-N 0.000 description 1
- XUNDRGZUFATOAN-UHFFFAOYSA-N 2-(4,7-dimethyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)acetic acid Chemical compound OC(=O)CC=1N2C3=CC(C)=CC=C3N(C)C2=NC=1C1=CC=CC=C1 XUNDRGZUFATOAN-UHFFFAOYSA-N 0.000 description 1
- BMLVZMPQXWRULH-UHFFFAOYSA-N 2-(4-methylphenyl)-3h-imidazo[1,2-a]benzimidazole Chemical compound C1=CC(C)=CC=C1C1=CN2C3=CC=CC=C3N=C2N1 BMLVZMPQXWRULH-UHFFFAOYSA-N 0.000 description 1
- VNZKTXZTVRKWEB-UHFFFAOYSA-N 2-(4h-imidazo[1,2-a]benzimidazol-1-yl)acetamide Chemical class C1=CC=C2N3C(CC(=O)N)=CN=C3NC2=C1 VNZKTXZTVRKWEB-UHFFFAOYSA-N 0.000 description 1
- WIYORVBIOFFKHY-UHFFFAOYSA-N 2-(6-chloro-4-methyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)-n-methylacetamide Chemical compound N1=C2N(C)C3=CC(Cl)=CC=C3N2C(CC(=O)NC)=C1C1=CC=CC=C1 WIYORVBIOFFKHY-UHFFFAOYSA-N 0.000 description 1
- GKXUYIJNHPHFJJ-UHFFFAOYSA-N 2-(6-chloro-4-methyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)acetic acid Chemical compound N1=C2N(C)C3=CC(Cl)=CC=C3N2C(CC(O)=O)=C1C1=CC=CC=C1 GKXUYIJNHPHFJJ-UHFFFAOYSA-N 0.000 description 1
- IPGSQPAZRSHPRJ-UHFFFAOYSA-N 2-(7-chloro-4-methyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)-n,n-dimethylacetamide Chemical compound N1=C2N(C)C3=CC=C(Cl)C=C3N2C(CC(=O)N(C)C)=C1C1=CC=CC=C1 IPGSQPAZRSHPRJ-UHFFFAOYSA-N 0.000 description 1
- SXZJWGVLSOZMQJ-UHFFFAOYSA-N 2-(7-chloro-4-methyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)-n-methylacetamide Chemical compound N1=C2N(C)C3=CC=C(Cl)C=C3N2C(CC(=O)NC)=C1C1=CC=CC=C1 SXZJWGVLSOZMQJ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZVHCHHREFOXZAU-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-4,7-dimethylimidazo[1,2-a]benzimidazol-1-yl]-n,n-dimethylacetamide Chemical compound N1=C2N(C)C3=CC=C(C)C=C3N2C(CC(=O)N(C)C)=C1C1=CC=C(Cl)C=C1 ZVHCHHREFOXZAU-UHFFFAOYSA-N 0.000 description 1
- VSSQJPRUHJGKRU-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-4,7-dimethylimidazo[1,2-a]benzimidazol-1-yl]-n-methylacetamide Chemical compound N1=C2N(C)C3=CC=C(C)C=C3N2C(CC(=O)NC)=C1C1=CC=C(Cl)C=C1 VSSQJPRUHJGKRU-UHFFFAOYSA-N 0.000 description 1
- QEXNROLKQFTAAI-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-4,7-dimethylimidazo[1,2-a]benzimidazol-1-yl]acetic acid Chemical compound OC(=O)CC=1N2C3=CC(C)=CC=C3N(C)C2=NC=1C1=CC=C(Cl)C=C1 QEXNROLKQFTAAI-UHFFFAOYSA-N 0.000 description 1
- XKQCQFWNHSUAFW-UHFFFAOYSA-N 2-[4-ethyl-2-(4-methylphenyl)imidazo[1,2-a]benzimidazol-1-yl]-n,n-dimethylacetamide Chemical compound N1=C2N(CC)C3=CC=CC=C3N2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 XKQCQFWNHSUAFW-UHFFFAOYSA-N 0.000 description 1
- WCTSXDFUCIOGGX-UHFFFAOYSA-N 2-[4-methyl-2-(4-methylphenyl)imidazo[1,2-a]benzimidazol-1-yl]acetic acid Chemical compound C1=CC(C)=CC=C1C1=C(CC(O)=O)N2C3=CC=CC=C3N(C)C2=N1 WCTSXDFUCIOGGX-UHFFFAOYSA-N 0.000 description 1
- QCWADZNHYZRNNN-UHFFFAOYSA-N 2-hydroxy-n,n-dimethyl-2-[4-methyl-2-(4-methylphenyl)imidazo[1,2-a]benzimidazol-1-yl]acetamide Chemical compound N1=C2N(C)C3=CC=CC=C3N2C(C(O)C(=O)N(C)C)=C1C1=CC=C(C)C=C1 QCWADZNHYZRNNN-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- VNDWQCSOSCCWIP-UHFFFAOYSA-N 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Chemical compound C1=2C=CNC(=O)C=2C2=CC(F)=CC=C2C2=C1NC(C(C)(C)C)=N2 VNDWQCSOSCCWIP-UHFFFAOYSA-N 0.000 description 1
- PEFBQDISJLYLTA-UHFFFAOYSA-N 3,6,7-trimethyl-2-phenyl-3a,4-dihydroimidazo[1,2-a]benzimidazole Chemical compound CN1C2NC3=CC(C)=C(C)C=C3N2C=C1C1=CC=CC=C1 PEFBQDISJLYLTA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100124609 Caenorhabditis elegans zyg-12 gene Proteins 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- VDTWXFMFBZRVQF-UHFFFAOYSA-N N1=C2NC3=CC=CC=C3N2C(C(O)C(=O)OCC)=C1C1=CC=C(C)C=C1 Chemical compound N1=C2NC3=CC=CC=C3N2C(C(O)C(=O)OCC)=C1C1=CC=C(C)C=C1 VDTWXFMFBZRVQF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- YGZQJTOFTKEILX-UHFFFAOYSA-N ethyl 2-[2-(4-methylphenyl)-4h-imidazo[1,2-a]benzimidazol-1-yl]acetate Chemical compound N1=C2NC3=CC=CC=C3N2C(CC(=O)OCC)=C1C1=CC=C(C)C=C1 YGZQJTOFTKEILX-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical class CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000001670 myorelaxant effect Effects 0.000 description 1
- IFICRCHGYDKQJF-UHFFFAOYSA-N n,n-dimethyl-2-(2-phenyl-4h-imidazo[1,2-a]benzimidazol-1-yl)acetamide Chemical compound N1=C2NC3=CC=CC=C3N2C(CC(=O)N(C)C)=C1C1=CC=CC=C1 IFICRCHGYDKQJF-UHFFFAOYSA-N 0.000 description 1
- DMJOCLILEXSRPB-UHFFFAOYSA-N n,n-dimethyl-2-(4,6,7-trimethyl-2-phenylimidazo[1,2-a]benzimidazol-1-yl)acetamide Chemical compound N1=C2N(C)C3=CC(C)=C(C)C=C3N2C(CC(=O)N(C)C)=C1C1=CC=CC=C1 DMJOCLILEXSRPB-UHFFFAOYSA-N 0.000 description 1
- BXOSYPQXRLRMME-UHFFFAOYSA-N n-methyl-2-[2-(4-methylphenyl)-4h-imidazo[1,2-a]benzimidazol-1-yl]acetamide Chemical compound N1=C2NC3=CC=CC=C3N2C(CC(=O)NC)=C1C1=CC=C(C)C=C1 BXOSYPQXRLRMME-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9300337A FR2700544B1 (fr) | 1993-01-15 | 1993-01-15 | Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique. |
| FR9309013A FR2707987B1 (fr) | 1993-07-22 | 1993-07-22 | Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique . |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK4694A3 true SK4694A3 (en) | 1995-02-08 |
Family
ID=26230029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK46-94A SK4694A3 (en) | 1993-01-15 | 1994-01-14 | 9h-imidazo (1,2,-a) benzimidazole-3-acetamide derivatives method of their preparation and pharmaceutical compounds containing these derivatives |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5466706A (https=) |
| EP (1) | EP0607076A1 (https=) |
| JP (1) | JPH06271575A (https=) |
| CN (1) | CN1097743A (https=) |
| AU (1) | AU665137B2 (https=) |
| CA (1) | CA2113490A1 (https=) |
| CZ (1) | CZ9394A3 (https=) |
| FI (1) | FI940186A7 (https=) |
| HU (1) | HUT70407A (https=) |
| IL (1) | IL108343A0 (https=) |
| NO (1) | NO940130L (https=) |
| NZ (1) | NZ250679A (https=) |
| PL (1) | PL301901A1 (https=) |
| RU (1) | RU94000725A (https=) |
| SK (1) | SK4694A3 (https=) |
| TW (1) | TW253886B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719843B1 (fr) * | 1994-05-10 | 1996-06-07 | Synthelabo | Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique. |
| FR2741073B1 (fr) * | 1995-11-09 | 1997-12-12 | Synthelabo | Derives de 4,5-dihydroimidazo(1,2-a)pyrrolo(1,2,3-cd) benzimidazole, leur preparation et leur application en therapeutique |
| GB9702524D0 (en) * | 1997-02-07 | 1997-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| FR2759698B1 (fr) * | 1997-02-20 | 1999-03-19 | Synthelabo | Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique |
| EP1318988A2 (en) * | 2000-09-11 | 2003-06-18 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| KR20040034594A (ko) * | 2001-01-26 | 2004-04-28 | 브리스톨-마이어스스퀴브컴파니 | 코르티코트로핀 방출 인자 억제제로서의 이미다졸릴 유도체 |
| ES2320758T3 (es) * | 2002-12-18 | 2009-05-28 | Mallinckrodt Inc. | Sintesis de heteroaril acetamidas. |
| FR2870239B1 (fr) * | 2004-05-11 | 2006-06-16 | Sanofi Synthelabo | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique. |
| ES2336126T3 (es) * | 2004-06-22 | 2010-04-08 | Mallinckrodt, Inc. | Sintesis de heteroarilacetamidas a partir de mezclas de reaccion que tienen un contenido reducido de agua. |
| KR101449057B1 (ko) * | 2006-03-17 | 2014-10-10 | 암비트 바이오사이언시즈 코포레이션 | 질환 치료용 이미다졸로티아졸 화합물 |
| EP2201018B1 (en) | 2007-09-19 | 2016-03-16 | Ambit Biosciences Corporation | Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-ethoxy)imidazoý2,1-b¨ý1,3¨benzothiazol-2-yl¨phenyl}urea, compositions thereof, and uses therewith |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3732243A (en) * | 1970-06-23 | 1973-05-08 | Sankyo Co | 2-(p-bromophenyl)-9-dimethyl-amino-propyl-9h-imidazo(1,2-a)benzimidazole |
| GB1484615A (en) * | 1974-11-23 | 1977-09-01 | Lepetit Spa | Tricyclic n-containing derivatives |
| FR2568879B1 (fr) * | 1984-08-07 | 1986-12-12 | Synthelabo | Imidazo(1,2-a)quinolines, leur preparation et leur application en therapeutique |
| US4675323A (en) * | 1985-08-06 | 1987-06-23 | Synthelabo | Imidazo(1,2-a)quinoline derivatives useful as anxiolytic agents |
| US5240944A (en) * | 1988-12-28 | 1993-08-31 | Kotobuki Seiyaku Co. Ltd. | Cyclic guanidine derivatives, anti-ulceratives and method of manufacturing the same |
-
1994
- 1994-01-11 EP EP94400057A patent/EP0607076A1/fr not_active Withdrawn
- 1994-01-14 RU RU94000725/04A patent/RU94000725A/ru unknown
- 1994-01-14 CZ CZ9493A patent/CZ9394A3/cs unknown
- 1994-01-14 SK SK46-94A patent/SK4694A3/sk unknown
- 1994-01-14 FI FI940186A patent/FI940186A7/fi unknown
- 1994-01-14 CN CN94100607A patent/CN1097743A/zh active Pending
- 1994-01-14 IL IL10834394A patent/IL108343A0/xx unknown
- 1994-01-14 PL PL94301901A patent/PL301901A1/xx unknown
- 1994-01-14 JP JP6002463A patent/JPH06271575A/ja active Pending
- 1994-01-14 US US08/180,998 patent/US5466706A/en not_active Expired - Fee Related
- 1994-01-14 NO NO940130A patent/NO940130L/no unknown
- 1994-01-14 HU HU9400109A patent/HUT70407A/hu unknown
- 1994-01-14 NZ NZ250679A patent/NZ250679A/en unknown
- 1994-01-14 AU AU53177/94A patent/AU665137B2/en not_active Ceased
- 1994-01-14 CA CA002113490A patent/CA2113490A1/en not_active Abandoned
- 1994-01-17 TW TW083100320A patent/TW253886B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| AU665137B2 (en) | 1995-12-14 |
| HUT70407A (en) | 1995-10-30 |
| NO940130D0 (no) | 1994-01-14 |
| RU94000725A (ru) | 1997-05-27 |
| FI940186A7 (fi) | 1994-07-16 |
| PL301901A1 (en) | 1994-07-25 |
| US5466706A (en) | 1995-11-14 |
| NZ250679A (en) | 1995-07-26 |
| TW253886B (https=) | 1995-08-11 |
| CA2113490A1 (en) | 1994-07-16 |
| JPH06271575A (ja) | 1994-09-27 |
| HU9400109D0 (en) | 1994-05-30 |
| IL108343A0 (en) | 1994-04-12 |
| CN1097743A (zh) | 1995-01-25 |
| FI940186A0 (fi) | 1994-01-14 |
| EP0607076A1 (fr) | 1994-07-20 |
| NO940130L (no) | 1994-07-18 |
| AU5317794A (en) | 1995-05-25 |
| CZ9394A3 (en) | 1994-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU744014B2 (en) | 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof | |
| CA2778680C (en) | N-containing heteroaryl derivatives as jak3 kinase inhibitors | |
| ES2430989T3 (es) | Compuesto anticancerígeno y composición farmacéutica que lo contiene | |
| SK278605B6 (en) | Substituted bridged diazabicycloalkylquinolone carboxylic acids, method of producing and pharmaceutical compositions containing them | |
| US6075021A (en) | 1H-pyrido[3,4-b]indole-4-carboxamide derivatives, preparation and application thereof in therapeutics | |
| JP2006516653A (ja) | キナーゼ阻害剤ピロロトリアジンの製造方法 | |
| SK4694A3 (en) | 9h-imidazo (1,2,-a) benzimidazole-3-acetamide derivatives method of their preparation and pharmaceutical compounds containing these derivatives | |
| ES2269822T3 (es) | Derivados de pirazol de anillos fusionados. | |
| US5512590A (en) | 5,6-dihydro-4h-imidazo 2',1':2,3!imidazo- 4,5,1-ij!quinoline and 4,5-dihydroimidazo- 1,2-a!pyrolo 1,2,3-cd!benzimidazole derivatives, their preparation and application in therapeutics | |
| US6262045B1 (en) | 4-Oxo-3,5-dihydro-4H-pyridazino[4,5-b]-indole-1-acetamide derivatives, their preparation and their application in therapy | |
| US20060173179A1 (en) | Azabenzoxazoles for the treatment of CNS disorders | |
| IE922342A1 (en) | Imidazo[2,1-b]benzothiazole-3-acetamide derivatives, their¹preparation and their use in therapeutics | |
| US20030191122A1 (en) | Carbamoyl tetrahydropyridine derivatives | |
| PL100184B1 (pl) | Sposob wytwarzania nowych pochodnych naftyrydynylo-piroliny | |
| CZ282959B6 (cs) | Derivát kyseliny 2-thienylimidazo/2,1-b/benzothiazol-3-octové, způsob jeho přípravy a farmaceutický přípravek tento derivát obsahující |